313 related articles for article (PubMed ID: 30809293)
21. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific
Nagy G; Dénes N; Kis A; Szabó JP; Berényi E; Garai I; Bai P; Hajdu I; Szikra D; Trencsényi G
Eur J Pharm Sci; 2017 Aug; 106():336-344. PubMed ID: 28625749
[TBL] [Abstract][Full Text] [Related]
22. Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.
Yao Z; Che XC; Lu R; Zheng MN; Zhu ZF; Li JP; Jian X; Shi LX; Liu JY; Gao WY
Mol Med; 2007; 13(1-2):14-21. PubMed ID: 17515953
[TBL] [Abstract][Full Text] [Related]
23. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
[TBL] [Abstract][Full Text] [Related]
24. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
25. The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
Liu KS; Ding WC; Wang SX; Liu Z; Xing GW; Wang Y; Wang YF
Oncol Rep; 2012 Jun; 27(6):1904-10. PubMed ID: 22447251
[TBL] [Abstract][Full Text] [Related]
26. [Inhibitory effect of tripeptide compound tyroservaltide on invasion and metastasis of mouse melanoma cell line B16-F10].
Che XC; Lu R; Hu JX; Zheng MN; Zhang MF; Wang S; Yu CY; Yang XL; Xing DH; Yao Z
Ai Zheng; 2006 Mar; 25(3):275-80. PubMed ID: 16536978
[TBL] [Abstract][Full Text] [Related]
27. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
28. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Dunphy MPS; Pressl C; Pillarsetty N; Grkovski M; Modi S; Jhaveri K; Norton L; Beattie BJ; Zanzonico PB; Zatorska D; Taldone T; Ochiana SO; Uddin MM; Burnazi EM; Lyashchenko SK; Hudis CA; Bromberg J; Schöder HM; Fox JJ; Zhang H; Chiosis G; Lewis JS; Larson SM
Clin Cancer Res; 2020 Oct; 26(19):5178-5187. PubMed ID: 32366671
[TBL] [Abstract][Full Text] [Related]
29. Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis.
Pan Y; Zhong LJ; Zhou H; Wang X; Chen K; Yang HP; Xiaokaiti Y; Maimaiti A; Jiang L; Li XJ
Acta Pharmacol Sin; 2012 Jun; 33(6):798-808. PubMed ID: 22669117
[TBL] [Abstract][Full Text] [Related]
30. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
31. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
[TBL] [Abstract][Full Text] [Related]
32. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells.
Humphries MJ; Yamada KM; Olden K
J Clin Invest; 1988 Mar; 81(3):782-90. PubMed ID: 3343338
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
35.
Kertész I; Vida A; Nagy G; Emri M; Farkas A; Kis A; Angyal J; Dénes N; Szabó JP; Kovács T; Bai P; Trencsényi G
J Cancer; 2017; 8(5):774-785. PubMed ID: 28382139
[TBL] [Abstract][Full Text] [Related]
36. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
[TBL] [Abstract][Full Text] [Related]
37. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
Irimura T; Gonzalez R; Nicolson GL
Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
[TBL] [Abstract][Full Text] [Related]
38. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.
Dakappagari N; Neely L; Tangri S; Lundgren K; Hipolito L; Estrellado A; Burrows F; Zhang H
Biomarkers; 2010 Feb; 15(1):31-8. PubMed ID: 19747088
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of HSP90 in melanoma.
Mielczarek-Lewandowska A; Hartman ML; Czyz M
Apoptosis; 2020 Feb; 25(1-2):12-28. PubMed ID: 31659567
[TBL] [Abstract][Full Text] [Related]
40. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
